Clinica chimica acta; international journal of clinical chemistry · 2026
Metabolic and mitochondrial alterations in children with autism spectrum disorder: The role of FGF-21 and GDF-15.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yildiz Ayla, Topuz Hanim Seyma, Onal Hasan
Аннотация
INTRODUCTION: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition marked by social communication deficits and repetitive behaviors. Evidence suggests that metabolic and mitochondrial stress contribute to ASD. Fibroblast growth factor 21 (FGF-21) and growth differentiation factor 15 (GDF-15) are circulating markers of mitochondrial dysfunction and cellular stress, but their role in pediatric ASD remains underexplored.
METHODS: Case-control study involved 118 children: 88 with ASD (DSM-5 criteria) and 30 healthy controls matched by age and sex. ASD patients were divided by Autism Behavior Checklist (ABC) scores into Group I (ABC >60, n = 48) and Group II (ABC ≤60, n = 40). FGF-21 and GDF-15 were measured by ELISA. Biochemical parameters, hemogram, plasma amino acids (LC-MS/MS), and urinary organic acids (GC-MS) were analyzed. Statistical analyses included Kruskal-Wallis, Spearman correlation and ROC.
RESULTS: FGF-21 was significantly elevated in ASD compared to controls (p < 0.0001), while GDF-15 showed no difference (p = 0.797). FGF-21 did not differ between Group I and Group II (p > 0.05). ASD showed increased lactate, lactate/pyruvate ratio, urea, AST, LDH, LDL, lymphocyte and platelet counts, and decreased pyruvate, serum and urinary creatinine (p < 0.05). Essential and branched-chain amino acids decreased, whereas glycine and histidine increased (p < 0.05). FGF-21 correlated weakly but significantly with mitochondrial dysfunction and amino acid metabolism markers. ROC showed good diagnostic accuracy for FGF-21 in ASD (AUC = 0.817), with 98.9% sensitivity and 73.3% specificity at 27.9 pg/mL cut-off. Urinary organic acids, methylmalonic acid, tiglylglycine, and 2-ketoisocaproic acid, were significantly elevated (p < 0.05).
CONCLUSION: Elevated serum FGF-21 in children with ASD is linked to metabolic alterations, whereas GDF-15 remains unchanged. These results suggest FGF-21's association with metabolic dysregulation in ASD.
METHODS: Case-control study involved 118 children: 88 with ASD (DSM-5 criteria) and 30 healthy controls matched by age and sex. ASD patients were divided by Autism Behavior Checklist (ABC) scores into Group I (ABC >60, n = 48) and Group II (ABC ≤60, n = 40). FGF-21 and GDF-15 were measured by ELISA. Biochemical parameters, hemogram, plasma amino acids (LC-MS/MS), and urinary organic acids (GC-MS) were analyzed. Statistical analyses included Kruskal-Wallis, Spearman correlation and ROC.
RESULTS: FGF-21 was significantly elevated in ASD compared to controls (p < 0.0001), while GDF-15 showed no difference (p = 0.797). FGF-21 did not differ between Group I and Group II (p > 0.05). ASD showed increased lactate, lactate/pyruvate ratio, urea, AST, LDH, LDL, lymphocyte and platelet counts, and decreased pyruvate, serum and urinary creatinine (p < 0.05). Essential and branched-chain amino acids decreased, whereas glycine and histidine increased (p < 0.05). FGF-21 correlated weakly but significantly with mitochondrial dysfunction and amino acid metabolism markers. ROC showed good diagnostic accuracy for FGF-21 in ASD (AUC = 0.817), with 98.9% sensitivity and 73.3% specificity at 27.9 pg/mL cut-off. Urinary organic acids, methylmalonic acid, tiglylglycine, and 2-ketoisocaproic acid, were significantly elevated (p < 0.05).
CONCLUSION: Elevated serum FGF-21 in children with ASD is linked to metabolic alterations, whereas GDF-15 remains unchanged. These results suggest FGF-21's association with metabolic dysregulation in ASD.